(Reuters) -U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical, deepening their use of artificial intelligence ...

Nabla to receive upfront and research cost payments in double-digit millions and eligible to receive success-based payments that may exceed $1 billion Multi-year partnership deploys Nabla Bio’s AI ...

This integration through the athenahealth Marketplace, is helping Nabla enable clinicians to complete documentation 24% faster and eliminate after-hours charting, easing one of the biggest burdens in ...

Ethics in artificial intelligence is important no matter the field, as it concerns not only vast amounts of data that needs to be protected, but there are also issues with biases, along with what many ...

Nabla is integrating its AI medical scribe with Navina's AI-enabled copilot to provide doctors with an AI layer that supports clinical workflows. The aim is to deliver real-time support through the ...

Ambient AI scribe company Nabla announced a partnership with Illinois-based Carle Health to implement its AI "copilot" technology into the health system's many hospitals and practices. The partnership ...

Many healthcare leaders are embracing agentic AI to enhance the clinician experience and strengthen their bottom line. Success depends on flexible solutions that amplify clinicians’ strengths while ...

Nabla, a leading provider of clinical AI assistants, has raised an additional $70 million in Series C funding, which brings total funding to $120 million, according to a company news release. The ...

Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now Nabla, a French startup building an AI ...

Healthcare has been pegged as a prime candidate for more AI applications — both to aid in clinical work and to lighten some of the more time-consuming administrative burdens that come around clinical ...